Efficacy News and Research

RSS

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

Biogen Idec and Swedish Orphan Biovitrum today announced that they plan to advance the companies' long-lasting, fully-recombinant factor VIII Fc fusion protein (rFVIIIFc) into a registrational clinical trial in people with hemophilia A. The decision to advance the program is based on promising data from a Phase 1/2a open-label, cross-over, multi-center, dose-escalation study that evaluated the safety and pharmacokinetics of an intravenous injection of rFVIIIFc in 16 previously-treated patients with severe hemophilia A.

12 Jul 2010

Multimedia talking touchscreens help end health disparities in underserved populations

Multimedia talking touchscreens, housed in computer kiosks at clinics and hospitals, are helping researchers at Northwestern University Feinberg School of Medicine and clinicians at local health care centers enhance patient-centered care for patients with diverse language, literacy and computer skills.

12 Jul 2010

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Results from a Phase III program evaluating imiquimod 3.75% and 2.5% creams for the treatment of EGW, applied once daily for up to 8 weeks, demonstrated that both were well-tolerated and more efficacious than placebo, according to data presented at the annual Human Papillomavirus Conference in Montreal, July 3 - 8. Investigators found that efficacy was greatest for imiquimod 3.75% with an enhanced safety profile.

9 Jul 2010

Pioneer Surgical Technology expands Biologics Product Specialist program

Pioneer Surgical Technology, Inc. recently expanded its Biologics Product Specialist program to provide sales and technical biologic expertise to support their growing line of products that address bone and soft tissue repair.

9 Jul 2010

MJFF awards $1.1M to six different projects for validating potential therapeutic targets for PD

The Michael J. Fox Foundation for Parkinson's Research today announced $1.1 million in total funding to six different projects aimed at validating potential therapeutic targets for Parkinson's disease.

9 Jul 2010

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia 2010 Congress taking place July 10-14, 2010, in Buenos Aires, Argentina. Key research includes a pre-clinical evaluation of recombinant factor Xa as a potential new approach to restoring hemostasis, as well as a study assessing the potential for an engineered recombinant factor VIIa molecule to improve therapeutic outcomes in mouse models of hemophilia.

9 Jul 2010

Phase II trial results of TB-402 presented at International Congress on Thrombosis

BioInvent International AB and ThromboGenics NV announce that the positive results from a Phase II trial of TB-402 (Anti-Factor VIII antibody) were presented at the 21st International Congress on Thrombosis in Milan, Italy yesterday. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

9 Jul 2010

Derma Sciences submits 510(k) application to FDA for MEDIHONEY Gel Wound & Burn Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces the achievement of regulatory and commercial milestones.

9 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Hormonal contraceptives are less effective for birth control in overweight or obese women: Study

As obesity continues to be a worldwide health risk, one of its "side effects" could include less effective birth control for overweight and obese women who use hormonal contraceptives.

9 Jul 2010

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

A University of Oklahoma researcher is developing a novel therapy for Alzheimer's disease using "biopharmaceutical proteases" to attack the toxic plaque that builds up in the brain of an Alzheimer's patient-an approach that he predicts will be lower in cost and higher in effectiveness than current therapies.

9 Jul 2010

Patients enrolled in CLARITY-AF study

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study, comparing the efficacy, safety and efficiency of CARTO 3 System guided radiofrequency ablation using the NAVISTAR THERMOCOOL catheter versus fluoroscopy guided radiofrequency ablation using the Pulmonary Vein Ablation catheter (Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

9 Jul 2010

IRIC scientists identify vitamin B3 as potential antifungal treatment

A team of scientists from the Institute for Research in Immunology and Cancer (IRIC) of the University of Montreal have identified vitamin B3 as a potential antifungal treatment. Led by IRIC Principal Investigators Martine Raymond, Alain Verreault and Pierre Thibault, in collaboration with Alaka Mullick, from the Biotechnology Research Institute of the National Research Council Canada, the study is the subject of a recent article in Nature Medicine.

9 Jul 2010

WSBI, University of Colorado sign licensing agreement for TCISM targets

Western States Biopharmaceuticals, Inc., a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.

8 Jul 2010

Alimera Sciences submits MAA for Iluvien to MHRA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals has submitted a Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom for Iluvien (fluocinolone acetonide intravitreal insert).

8 Jul 2010

Article related to MN-166 mechanism of action included in PNAS USA

MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported that the June 22, 2010 issue of Proceedings of the National Academy of Sciences USA included an article related to the mechanism of action of MN-166 (ibudilast), as an emerging therapeutic for neurological disorders.

8 Jul 2010

Optics Express publishes special focus issue on lung cancer imaging research

Advanced imaging technologies that promise to improve the development of effective drugs to treat lung cancer are the focus of the current special issue of Optics Express, an open-access journal published by the Optical Society (OSA). Research featured in the special focus issue on Imaging in Diagnosis and Treatment of Lung Cancer outlines standardized approaches to measure and compare tumor size, as well as to validate the accuracy of such measurements under defined settings.

8 Jul 2010

Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology

Silence Therapeutics plc announces the issuance of United States patent 7,750,144, titled Methods and Compositions for Enhancing Efficacy and Specificity of RNA Silencing, by the United States Patent and Trademark Office (USPTO). The issued patent generally claims methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. The ability to minimize the off-target effects of RNAi therapeutics is critical for controlling unwanted cellular activity and/or potential safety concerns.

8 Jul 2010

Researchers evaluate safety and feasibility of STARR procedure for ODS

Obstructed defecation syndrome represents a widespread clinical problem which frequently affects middle-aged females. Nevertheless, many of the previously established techniques are unsuitable for patients with ODS associated with simultaneous rectocele and rectal intussusception. Notably, STARR has been proposed as an alternative operation and a relatively noninvasive surgical technique for this difficult problem.

8 Jul 2010

Ethicon launches OMNEX Surgical synthetic sealant

Ethicon, Inc., a worldwide leader in surgical care, announced today the introduction of ETHICON™ OMNEX™ Surgical Sealant, ETHICON™ Biosurgery's first synthetic sealant designed to achieve adjunctive hemostasis (stoppage of bleeding) in vascular reconstructions by mechanically sealing areas of leakage. The US Food and Drug Administration (FDA) recently granted approval of the Premarket Approval Application (PMA) for ETHICON™ OMNEX™ Surgical Sealant.

8 Jul 2010

Efficacy News and Research

Biogen Idec, Swedish Orphan Biovitrum announce advancement of rFVIIIFc into registrational study

Multimedia talking touchscreens help end health disparities in underserved populations

Phase III study results of imiquimod creams for treatment of EGW presented at HPV Conference

Pioneer Surgical Technology expands Biologics Product Specialist program

MJFF awards $1.1M to six different projects for validating potential therapeutic targets for PD

Pfizer to present results of hemophilia studies at WFH 2010 Congress

Phase II trial results of TB-402 presented at International Congress on Thrombosis

Derma Sciences submits 510(k) application to FDA for MEDIHONEY Gel Wound & Burn Dressing

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Hormonal contraceptives are less effective for birth control in overweight or obese women: Study

Researcher uses biopharmaceutical proteases to develop novel therapy for Alzheimer's disease

Patients enrolled in CLARITY-AF study

IRIC scientists identify vitamin B3 as potential antifungal treatment

WSBI, University of Colorado sign licensing agreement for TCISM targets

Alimera Sciences submits MAA for Iluvien to MHRA

Article related to MN-166 mechanism of action included in PNAS USA

Optics Express publishes special focus issue on lung cancer imaging research

Silence strengthens RNAi IP portfolio with issuance of key patent in structural modification technology

Researchers evaluate safety and feasibility of STARR procedure for ODS

Ethicon launches OMNEX Surgical synthetic sealant

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News